Pegaspargase-related outcome and toxicity analysis. (A) 3-year DFS per the cumulative pegaspargase dose (IU/m2) administered at cycles (C) 1 and 2: ≤6000 IU/m2, 60% (95% CI, 50-72) vs >6000 IU/m2, 64% (95% CI, 55-76), that is, below or above the total median dose received at C1 and C2; the higher dose usually meant the full administration of the first 2 planned protocol doses. (B) 3-year DFS per BMI: BMI of ≤30, 63% (95% CI, 55-71) vs >30, 73% (95% CI, 53-100), P = .31. (C) Correlative analyses between BMI, cumulative pegaspargase dosing at cycles C1 and C2, and occurrence of grade (G) ≥2 severe adverse events (SAEs) in individual patients (nonsignificant P values). (D) Correlative analyses between BMI, cumulative pegaspargase dosing at C1 and C2, and SAE grading (nonsignificant P values). (E) Correlative analyses between BMI, cumulative pegaspargase dosing at C1 and 2, occurrence of SAE G ≥2, and age groups (nonsignificant P values). Scatter plots in panels C-E with linear model function to depict the correlation index.
